Diagnosis, treatment, and prognosis of primary intraocular lymphoma: Single‐center real‐world clinical experience
Cancer Medicine · 2023
DOI: 10.1002/cam4.5567 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Medicine, 2023. Verfasst von Gi-June Min und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Catholic University Lymphoma Group, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul…. Hauptthemen laut MEDLINE: Intraocular Lymphoma, Central Nervous System Neoplasms. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
The diagnosis and management of primary intraocular lymphoma (PIOL) remain challenging. This study identified factors indicative of PIOL, described treatment outcomes, and determined modalities to prevent relapse.
Methods
We included 21 PIOL‐diagnosed patients, seven via cytology, 12 via genetic evaluation, and two via interleukin (IL) level measurements, who underwent vitrectomy and received local intravitreal methotrexate (IV‐MTX) injection. Clinical outcomes, including treatment response and relapse, were compared between patients receiving IV‐MTX alone (n = 13) or IV‐MTX with systemic high‐dose methotrexate (HD‐MTX) as prophylaxis (n = 8).
Results
Twelve ophthalmologic and eight central nervous system (CNS) relapse cases within a median of 20.3 and 11.6 months were shown, regardless of the treatment modalities, with a median progression‐free survival of 21.3 (95% confidence interval, 9.5–36.7) months. There was no difference in demographic characteristics between the two groups, except with the poorer performance status in patients in the HD‐MTX prophylaxis group. Furthermore, patients demonstrated rapid elevations in the vitreous fluid IL‐10/IL‐6 cytokine ratio before ophthalmologic and CNS relapse. Therefore, diagnosis should be based on clinical signs and assisted by vitrectomy, cytologic, molecular, and cytokine studies.
Conclusion
For PIOL, aggressive systemic treatment equivalent to that of primary CNS lymphoma (PCNSL) is recommended because solely HD‐MTX did not prevent or delay CNS relapse. To prevent PIOL relapse in the CNS efficiently, prospective trials with large numbers of patients and advanced therapeutic regimens are necessary. Furthermore, regular clinical follow‐up is crucial, and the IL‐10/IL‐6 ratio can help evaluate relapse promptly.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hematology, Catholic University Lymphoma Group, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.
- Department of Hematology, Catholic University Lymphoma Group, Yeouido St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.
- Department of Nuclear Medicine, Catholic University Lymphoma Group, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.
- Department of Radiation Oncology, Catholic University Lymphoma Group, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.
- Department of Hospital Pathology, Catholic University Lymphoma Group, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.
- Department of Ophthalmology and Visual Science, Catholic University Lymphoma Group, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.
ORCID-Profile: Gi-June Min, Young-Woo Jeon, Seok-Goo Cho
Zitieren
APA
Min, G. J., Kim, T. Y., Jeon, Y. W., O, J. H., Choi, B. O., Park, G., Park, Y. H., & Cho, S. G. (2023). Diagnosis, treatment, and prognosis of primary intraocular lymphoma: Single‐center real‐world clinical experience. Cancer Medicine. https://doi.org/10.1002/cam4.5567
Vancouver
Min GJ, Kim TY, Jeon YW, O JH, Choi BO, Park G, et al. Diagnosis, treatment, and prognosis of primary intraocular lymphoma: Single‐center real‐world clinical experience. Cancer Medicine. 2023. doi:10.1002/cam4.5567
BibTeX
@article{Min2023,
author = {Min, Gi-June and Kim, Tong Yoon and Jeon, Young-Woo and O, Joo Hyun and Choi, Byung-Ock and Park, Gyeongsin and Park, Young-Hoon and Cho, Seok-Goo},
title = {Diagnosis, treatment, and prognosis of primary intraocular lymphoma: Single‐center real‐world clinical experience},
journal = {Cancer Medicine},
year = {2023},
doi = {10.1002/cam4.5567}
}
EUVIMED